(NASDAQ: XLO) Xilio Therapeutics's forecast annual revenue growth rate of -20.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Xilio Therapeutics's revenue in 2026 is $53,484,000.On average, 2 Wall Street analysts forecast XLO's revenue for 2026 to be $165,024,648, with the lowest XLO revenue forecast at $160,124,703, and the highest XLO revenue forecast at $171,563,891. On average, 2 Wall Street analysts forecast XLO's revenue for 2027 to be $443,531,786, with the lowest XLO revenue forecast at $430,357,575, and the highest XLO revenue forecast at $461,097,402.
In 2028, XLO is forecast to generate $48,885,777 in revenue, with the lowest revenue forecast at $47,431,948 and the highest revenue forecast at $50,824,217.